Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nina Ditsch

Showing results (181-190 of 207) with videos related to

Pageof 21
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 22, 2025
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025Toralf Reimer, Thorsten Kuehn, Volkmar Mueller, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2026
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 StudyMaggie Banys-Paluchowski, Steffi Hartmann, Jana de Boniface, et al.
The British Journal of Surgery|September 18, 2025
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort studyThorsten Kühn, Maggie Banys-Paluchowski, Nina Ditsch, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
JAMA Oncology|April 25, 2024
Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant ChemotherapyGiacomo Montagna, Mary M Mrdutt, Susie X Sun, et al.
Human Molecular Genetics|September 6, 2011
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriersDavid G Cox, Jacques Simard, Daniel Sinnett, et al.
Human Molecular Genetics|August 7, 2009
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriersAntonis C Antoniou, Olga M Sinilnikova, Lesley McGuffog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk ScoresJulie Lecarpentier, Valentina Silvestri, Karoline B Kuchenbaecker, et al.
Breast Cancer Research : BCR|February 22, 2012
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriersAntonis C Antoniou, Karoline B Kuchenbaecker, Penny Soucy, et al.
Pageof 21

Showing results (181-190 of 207) with videos related to

Sort By:
Pageof 21
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 22, 2025
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025Toralf Reimer, Thorsten Kuehn, Volkmar Mueller, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2026
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 StudyMaggie Banys-Paluchowski, Steffi Hartmann, Jana de Boniface, et al.
The British Journal of Surgery|September 18, 2025
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort studyThorsten Kühn, Maggie Banys-Paluchowski, Nina Ditsch, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
JAMA Oncology|April 25, 2024
Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant ChemotherapyGiacomo Montagna, Mary M Mrdutt, Susie X Sun, et al.
Human Molecular Genetics|September 6, 2011
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriersDavid G Cox, Jacques Simard, Daniel Sinnett, et al.
Human Molecular Genetics|August 7, 2009
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriersAntonis C Antoniou, Olga M Sinilnikova, Lesley McGuffog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk ScoresJulie Lecarpentier, Valentina Silvestri, Karoline B Kuchenbaecker, et al.
Breast Cancer Research : BCR|February 22, 2012
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriersAntonis C Antoniou, Karoline B Kuchenbaecker, Penny Soucy, et al.
Pageof 21